MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Ocular Therapeutix Inc

Gesloten

SectorGezondheidszorg

10.97 -0.9

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.9

Max

11.28

Belangrijke statistieken

By Trading Economics

Inkomsten

-16M

-64M

Verkoop

-6.4M

11M

Winstmarge

-602.342

Werknemers

274

EBITDA

-20M

-64M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+51.35% upside

Dividenden

By Dow Jones

Volgende Winsten

5 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

206M

1.5B

Vorige openingsprijs

11.87

Vorige sluitingsprijs

10.97

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Ocular Therapeutix Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 jul 2025, 22:19 UTC

Acquisities, Fusies, Overnames

FCC Approves U.S. Cellular Sale to T-Mobile

11 jul 2025, 17:28 UTC

Belangrijke Marktbewegers

SharpLink Gaming Gains on Ethereum Purchase

11 jul 2025, 16:57 UTC

Winsten

BASF Cuts Outlook on Global Economy Uncertainty

11 jul 2025, 21:45 UTC

Marktinformatie

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 jul 2025, 19:46 UTC

Acquisities, Fusies, Overnames

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 jul 2025, 19:45 UTC

Marktinformatie

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 jul 2025, 19:05 UTC

Marktinformatie

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 jul 2025, 18:18 UTC

Marktinformatie

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 jul 2025, 17:35 UTC

Marktinformatie

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 jul 2025, 17:26 UTC

Marktinformatie

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 jul 2025, 16:53 UTC

Marktinformatie

Crude Futures Add to Early Gains -- Market Talk

11 jul 2025, 16:42 UTC

Winsten

BASF Cuts Outlook on Global Economic Uncertainty

11 jul 2025, 16:08 UTC

Marktinformatie

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 jul 2025, 16:05 UTC

Winsten

BASF Will Publish Half-Year Results on July 30

11 jul 2025, 16:04 UTC

Marktinformatie

Global Equities Roundup: Market Talk

11 jul 2025, 16:04 UTC

Marktinformatie

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 jul 2025, 16:03 UTC

Winsten

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 jul 2025, 16:02 UTC

Winsten

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 jul 2025, 16:01 UTC

Winsten

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 jul 2025, 16:00 UTC

Winsten

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 jul 2025, 15:59 UTC

Winsten

BASF Cuts 2025 Earnings View

11 jul 2025, 15:58 UTC

Winsten

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 jul 2025, 15:57 UTC

Winsten

BASF 2Q EBIT Before Special Items EUR810M

11 jul 2025, 15:54 UTC

Winsten

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 jul 2025, 15:54 UTC

Winsten

BASF 2Q Sales Fell 2.1% on Year

11 jul 2025, 15:53 UTC

Winsten

BASF 2Q Sales EUR15.77B

11 jul 2025, 15:52 UTC

Winsten

BASF: This Was in Line With Consensus Estimates

11 jul 2025, 15:52 UTC

Winsten

BASF 2Q Ebitda Before Special Items EUR1.77B

11 jul 2025, 15:49 UTC

Winsten

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 jul 2025, 15:41 UTC

Marktinformatie

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Peer Vergelijking

Prijswijziging

Ocular Therapeutix Inc Prognose

Koersdoel

By TipRanks

51.35% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 16.77 USD  51.35%

Hoogste 22 USD

Laagste 8.5 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ocular Therapeutix Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Technische score

By Trading Central

6.97 / 7.62Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.